Related Experiment Video

Updated: Jun 5, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review

A K Sjølie1, P Dodson, F R R Hobbs

  • 1Department of Ophthalmology, University of Southern Denmark. A.K.Sjoelie@ouh.regionsyddanmark.dk

International Journal of Clinical Practice
|January 18, 2011
PubMed

Insights

Renin-angiotensin system (RAS) blockade shows promise in preventing diabetic retinopathy. Studies suggest RAS inhibitors may reduce retinopathy severity and progression in diabetes patients.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic retinopathy is a major microvascular complication of diabetes, necessitating preventative strategies beyond glycemic and blood pressure control.
  • The renin-angiotensin system (RAS) is implicated in retinopathy development and progression.
  • Current management often focuses on treatment rather than primary or secondary prevention of retinopathy.

Purpose of the Study:

  • To investigate the role of renin-angiotensin system (RAS) blockade in the prevention of diabetic retinopathy.
  • To evaluate the efficacy of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors in managing retinopathy.

Main Methods:

  • Review of the DIRECT program, assessing the ARB candesartan in type 1 and type 2 diabetes.
  • Analysis of the RASS trial, examining ARB losartan and ACE inhibitor enalapril in type 1 diabetes.
  • Discussion of clinical implications of RAS blockade in retinopathy.

Main Results:

  • The DIRECT program did not meet primary endpoints, but showed a trend towards less severe retinopathy with RAS blockade.
  • The RASS trial reported reduced retinopathy progression in type 1 diabetes with both ARB and ACE inhibitor therapy.
  • RAS blockade demonstrates potential in mitigating retinopathy severity and progression.

Conclusions:

  • RAS blockade represents a potential therapeutic strategy for preventing and managing diabetic retinopathy.
  • Further research is warranted to establish the definitive role of RAS inhibitors in diabetic eye care.
  • Targeting the intraocular RAS may offer new avenues for retinopathy prevention in diabetic patients.

More Related Videos

Retinal Pathophysiological Evaluation in a Rat Model09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Trypsin Digest Protocol to Analyze the Retinal Vasculature of a Mouse Model09:03

Trypsin Digest Protocol to Analyze the Retinal Vasculature of a Mouse Model

Published on: June 13, 2013

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...